eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2021-06-30 14 2 793 802 10.13005/bpj/2182 38801 article Arunkumar R 1 MaignanaKumar R 1 Duraivel M 1 AhamedBasha A 2 Amalan Stanley V 3 Ruckmani A 1 Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Chennai-603103, Tamil Nadu, India. Department of Physiology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Chennai-603103, Tamil Nadu, India. Scientific and Academic advisor, International Institute of Biotechnology and Toxicology, Padappai, Kanchipuram-601301, Tamil Nadu, India. The objective was to evaluate the efficacy of Vipro^TM, a polyherbal formulation in the management of uncomplicated respiratory infection towards reducing the severity of clinical symptoms, reducing the worsening of clinical symptoms&complications and to determine its safety by detectingadverse events. The study was started after obtaining approval from Institutional Human Ethics Committee. It was a prospective, randomized controlled study done in 60 patients. Patients having uncomplicated respiratory infections, at least for less than 5 days, with clinical symptoms and signs of fever, myalgia, rhinitis, sore throat, throat pain, cough, expectoration and head ache were enrolled and randomly allocated to one of the three groups, A, B and C. Group A received standard treatment, group B Vipro^TM and group C Vipro^TM along with the standard treatment. All the patients were followed up for a period of 7 days from starting treatment. Telephonic follow up was done daily for 7 days and physical follow up on day 0, day 4 and day 7. During physical follow up, vitals & body temperature were recorded, general and systemic examination done, adverse events were noted and improvement in constitutional symptoms was assessed. Complete blood count (CBC) and nasal / throat swab for culture were done at the baseline and at the end of study. Vipro ^TM has demonstrated efficacy in alleviating the clinical symptoms similar to standard treatment. With regard to safety, Vipro^TM is associated with a few adverse events and all of them are minor in nature and subsided within 24 hours. https://biomedpharmajournal.org/vol14no2/a-single-centre-prospective-randomized-open-labelled-clinical-study-to-evaluate-the-effectiveness-of-siddha-poly-herbal-formulation-viprotm-towards-the-management-of-uncomplicated-respiratory-inf/ Poly Herbal Formulation Respiratory Infection Siddha Vipro^TM